Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
3
30%
Ph not_applicable
1
10%

Phase Distribution

6

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 23 (30.0%)
N/A1 (10.0%)

Trials by Status

completed660%
terminated330%
withdrawn110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

NCT00074698
completedphase_1

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559
completedphase_2

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

NCT01262001
completedphase_1

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

NCT00754143
terminatedphase_1

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT00782561
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00074698Phase 1

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Completed
NCT02210559Phase 1

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Completed
NCT01262001Phase 2

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Completed
NCT00754143Phase 1

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Completed
NCT00782561Phase 1

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Terminated
NCT00913393Phase 2

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Terminated
NCT02851381Not Applicable

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Withdrawn
NCT01217632Phase 2

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Terminated
NCT01181245Phase 1

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed
NCT00102297Phase 1

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10